Laura Keren Urbina-Jara

Mrs. Laura Keren Urbina-Jara

Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2019 in Genes
Verified
Journal Article
Open access
PDF file
Laura Keren Urbina-JaraLaura Keren Urbina-Jara
Laura Keren Urbina-Jara
ARAUGUSTO ROJAS-MARTINEZ
AUGUSTO ROJAS-MARTINEZ
EMEmmanuel Martinez-Ledesma
Emmanuel Martinez-Ledesma
DADione Aguilar
Dione Aguilar
CVCynthia Villarreal-Garza
Cynthia Villarreal-Garza
RORocio Ortiz-Lopez
Rocio Ortiz-Lopez
Germline mutations in BRCA1 and BRCA2 (BRCA1/2) genes are present in about 50% of cases of hereditary breast cancer. Proteins encoded by these genes are key players in DNA repair by homologous recombination (HR). Advances in next generation sequencing and gene panels for breast cancer testing have generated a large amount of data on gene variants implicated in hereditary breast cancer, particularly in genes such as PALB2, ATM, CHEK2, RAD51, MSH2, and BARD1. These genes are involved in DNA repair. Most of these variants have been reported for Caucasian, Jewish, and Asian population, with few reports for other communities, like those in Latin American (LA) countries. We reviewed 81 studies from 11 LA countries published between 2000 and 2019 but most of these studies focused on BRCA1/2 genes. In addition to these genes, breast cancer-related variants have been reported for PALB2, ATM, CHEK2, BARD1, MLH1, BRIP1, MSH2, NBN, MSH6, and PMS2 genes. Some of these variants are unique to LA populations. This analysis may contribute to enhance breast cancer variant characterization, and thus to find therapies and implement precision medicine for LA communities.

Verified
Journal Article
Open access
PDF file
Laura Keren Urbina-JaraLaura Keren Urbina-Jara
Laura Keren Urbina-Jara
EMEmmanuel Martinez-Ledesma
Emmanuel Martinez-Ledesma
ARAUGUSTO ROJAS-MARTINEZ
AUGUSTO ROJAS-MARTINEZ
FRFrancisco Ricardo Rodriguez-Recio
Francisco Ricardo Rodriguez-Recio
RORocio Ortiz-Lopez
Rocio Ortiz-Lopez
The prevalence of breast cancer in young women (YWBC) has increased alarmingly. Significant efforts are being made to elucidate the biological mechanisms concerning the development, prognosis, and pathological response in early-onset breast cancer (BC) patients. Dysfunctional DNA repair proteins are implied in BC predisposition, progression, and therapy response, underscoring the need for further analyses on DNA repair genes. Public databases of large patient datasets such as METABRIC, TCGA, COSMIC, and cancer cell lines allow the identification of variants in DNA repair genes and possible precision drug candidates. This study aimed at identifying variants and drug candidates that may benefit Latin American (LA) YWBC. We analyzed pathogenic variants in 90 genes involved in DNA repair in public BC datasets from METABRIC, TCGA, COSMIC, CCLE, and COSMIC Cell Lines Project. Results showed that reported DNA repair germline variants in the LA dataset are underrepresented in large databases, in contrast to other populations. Additionally, only six gene repair variants in women under 50 years old from the study population were reported in BC cell lines. Therefore, there is a need for new approaches to study DNA repair variants reported in young women from LA.